Melanoma | Breakfast with the Investigators: Management of Melanoma

1:02:00
 
Share
 

Manage episode 238209949 series 1464173
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Georgina Long and Drs Jason J Luke and Jeffrey S Weber.

  • Introduction (00:00)
    • Program overview: Dr Love
  • Adjuvant Systemic Therapy of Melanoma (1:33)
  • Case (Dr Weber): A man in his early 50s with melanoma and a BRAF V600E tumor mutation who received adjuvant dabrafenib/trametinib (7:20)
  • Case (Prof Long): A man in his mid-60s with BRAF wild-type melanoma who developed a local recurrence after adjuvant nivolumab (9:28)
  • Case (Dr Luke): A woman in her mid-40s with BRAF wild-type melanoma who received adjuvant nivolumab and developed immune-related hypothyroidism (15:22)
  • BRAF/MEK Inhibitor Combinations in the Management of Metastatic Melanoma (24:52)
  • Case (Prof Long): A woman in her mid-70s with newly diagnosed metastatic melanoma and a BRAF V600K tumor mutation who received encorafenib/binimetinib (37:40)
  • Case (Dr Luke): A man in his mid-50s with metastatic melanoma and a BRAF tumor mutation who developed brain metastases (42:02)
  • Immune Checkpoint Inhibitors in the Management of Metastatic Melanoma (48:25)
  • Case (Dr Weber): A man in his late 30s with metastatic BRAF wild-type melanoma, including brain metastases, who experienced disease progression on single-agent anti-PD-1 antibody therapy and was switched to nivolumab/ipilimumab (50:22)

Select publications

2183 episodes